New Blood Test Option for Colorectal Cancer Screening

The American Cancer Society (ACS) has expanded its colorectal cancer screening recommendations to include blood-based tests, marking a significant shift in proactive health measures. This new guideline, effective as of 2026-05-27T12:36:15+00:00, is particularly aimed at individuals aged 45 and older who are at average risk but have declined traditional visual or stool-based screenings.

The Shield test, a specific blood test approved by the US FDA in 2024, is now recommended by the ACS. It is designed to detect tumor DNA shed into the bloodstream, demonstrating an 83% sensitivity for colorectal cancer. However, it is noted to be less effective at identifying precancerous polyps compared to other methods.

This inclusion aims to address the concerning rise in colorectal cancer among younger adults; it is now the leading cancer killer for Americans under 50. Despite available screenings, approximately one in three eligible adults remain unscreened, highlighting a critical public health challenge that the ACS hopes to mitigate with more accessible options.

While colonoscopies remain the gold standard, the ACS acknowledges that barriers exist for many individuals. The new guideline also incorporates upgraded stool-based tests like Cologuard Plus and ColoSense. These additions are intended to broaden screening capture, especially in younger, vulnerable populations who might otherwise forgo testing altogether.